ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea
June 02 2022 - 6:34AM
Business Wire
Tru Niagen® enters the international market
with digital cross-border launch strategy
ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with
Juvenis to conduct cross-border sales of Tru Niagen® in South
Korea. Juvenis is a Korean healthcare marketing company with a
focus on the cosmetic and dietary supplement industries. With
strong partnerships in a dynamic and trend-setting Korean market,
Juvenis emphasizes products with differentiated science and proven
benefits.
Tru Niagen® is one of Amazon’s top-selling brands in the Vitamin
B3 category for boosting NAD+ levels and features ChromaDex’s
proprietary ingredient, Niagen® (patented nicotinamide riboside or
NR). Between 2019 and 2050, the Republic of Korea is expected to
experience the highest increase in its share of older persons, with
a 23% increase in those 65 years or older. Nine out of the 10
countries with the largest percentage increase in the share of
older persons in the world will be in Eastern and South-Eastern
Asia (United Nations).
“As a pioneer of NAD+ research, we are committed to helping
communities abroad discover the benefits of cellular energy,
defense, repair, and vitality as they age. It is our goal to
provide global access to Tru Niagen® and are thrilled to partner
with Juvenis to bring its proven benefits to South Korea,” said
Frank Jaksch, Co-Founder and Executive Chairman of ChromaDex.
Just this April 2022, Dr. Charles Brenner (Alfred E Mann Family
Foundation Chair in Diabetes and Cancer Metabolism at City of Hope
National Medical Center and ChromaDex Chief Scientific Advisor)
spoke about innovations in metabolism, including the importance of
NR, at K.E.Y. Platform in Seoul, South Korea.
Tru Niagen® will be available for sale in the South Korean
market on several cross-border marketplaces including
NaverSmartStore, 11thStreet, kakaoStore, Gmarket, Auction, and will
also be available on www.TruNiagenKorea.com.
“We are pleased to execute a partnership with ChromaDex for the
South Korean market,” said Dongyeon Kim, CEO of Juvenis. “With a
strong collaboration between ChromaDex and Juvenis, we look forward
to building a prosperous long-term business together. Above all, we
are looking forward to working with ChromaDex to help the Korean
community age healthier.”
NR, the key ingredient in Tru Niagen®, is the world’s most
efficient NAD+ precursor on the market, particularly over NMN
(nicotinamide mononucleotide). Supplementation with Niagen® is
backed by 20 published and peer-reviewed clinical trials. Niagen®
has achieved regulatory acceptance for use in supplements by the US
FDA. Additionally, Niagen® has been approved for use in food
supplements by the European Commission, complementary medicines by
the Therapeutic Goods Administration of Australia (TGA), medical
foods by the Brazilian Health Regulatory Agency (ANVISA), and
medical foods by the Food Standards Australia New Zealand (FSANZ).
Tru Niagen® has also been approved by Health Canada as a Natural
Health Product. Additionally, ChromaDex continues to lead the
industry in NAD+ research and recently announced that the ChromaDex
External Research Program (CERPTM) reached over 250 material
transfer agreements (MTAs) featuring Niagen® and other proprietary
ingredients.
For additional information on the science supporting Niagen®
visit www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
About Juvenis:
Juvenis is a Korean life sciences company with focus on
healthcare. With strong partnerships in a dynamic and trend-setting
market, Juvenis is focused on marketing products with defensible
science with proven benefits. The pipeline of products include
healthcare to skincare.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to global access of NIAGEN®.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be idntified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,"
"possible," "probable," "believes," "seeks," "may," "will,"
"should," "could" or the negative of such terms or other similar
expressions. Risks that contribute to the uncertain nature of these
forward-looking statements include the impact of the COVID-19
pandemic on our business and the global economy; our history of
operating losses and need to obtain additional financing; the
growth and profitability of our product sales; our ability to
maintain sales, marketing and distribution capabilities; changing
consumer perceptions of our products; our reliance on a single or
limited number of third-party suppliers; and the risks and
uncertainties associated with our business and financial condition.
More detailed information about ChromaDex and the risk factors that
may affect the realization of forward-looking statements is set
forth in ChromaDex's Annual Report on Form 10-K for the fiscal year
ended December 31, 2021, ChromaDex's Quarterly Reports on Form 10-Q
and other filings submitted by ChromaDex to the SEC, copies of
which may be obtained from the SEC's website at www.sec.gov.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and actual results may differ materially from those suggested by
these forward-looking statements. All forward-looking statements
are qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220602005177/en/
ChromaDex Media Contact: Kendall Knysch, Director of
Media Relations 310-388-6706 ext. 689 kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber, Vice
President of Finance and Investor Relations 949-419-0288 ext. 127
briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024